Urologix Reports Results for Fourth Quarter and Fiscal Year 2012
August 23, 2012 16:00 ET
|
21st North Inc.
Fiscal year 2012 revenue increased 35% over the fiscal year 2011 period in line with annual guidance
Fourth quarter revenue of $4.5 million up 54% year-over-year and down 5%...
Urologix Announces Closing of Over-Allotment Option
August 07, 2012 13:00 ET
|
21st North Inc.
MINNEAPOLIS, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the...
Urologix Regains NASDAQ Compliance With Minimum Shareholders' Equity Requirement
July 18, 2012 14:00 ET
|
21st North Inc.
MINNEAPOLIS, July 18, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today it...
Urologix Announces Closing of Follow-On Offering
July 05, 2012 11:00 ET
|
21st North Inc.
MINNEAPOLIS, July 5, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the...
Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock
June 29, 2012 09:21 ET
|
21st North Inc.
MINNEAPOLIS, June 29, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced...
Urologix Announces Three Events at the 107th Annual Meeting of the American Urological Association
May 14, 2012 16:06 ET
|
21st North Inc.
Sponsor of Expert Panel Lecture on In-Office BPH Therapies, Moderated by Dr. Claus Roehrborn
Presentation of Cooled ThermoTherapy™ (CTT) Clinical Outcomes for Improving Nocturia by Dr....
Urologix Reports 59% Increase in Revenue Year-Over-Year for Fiscal 2012 Third Quarter
April 26, 2012 16:00 ET
|
21st North Inc.
$4.7 million in total revenue, up 2% sequentially
Positive cash flow in the quarter of $285 thousand
Full year 2012 revenue guidance between $17.0 to $17.5 million
MINNEAPOLIS, April...
Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter
January 24, 2012 16:00 ET
|
21st North Inc.
$4.7 million in revenue, 40% quarterly revenue growth year over year
Positive cash flow in the quarter of $17 thousand
$2 million credit facility established
MINNEAPOLIS, Jan. 24, 2012...
Urologix Secures $2 Million Credit Facility
January 12, 2012 16:00 ET
|
21st North Inc.
MINNEAPOLIS, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX), the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective...
Urologix Regains Nasdaq Minimum Bid Price Requirement
January 06, 2012 15:00 ET
|
21st North Inc.
MINNEAPOLIS, Jan. 6, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX) is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective...